AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9510041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 422
Study 7483066 — intervention group
Group type: EXPERIMENTAL
Intervention: Staged resection (group T)
Number of subjects: 121
Study 7483066 — intervention group
Group type: COMPARATOR
Intervention: Acute resection (group R)
Number of subjects: 121
Study 2218184 — intervention group
Group type: EXPERIMENTAL
Intervention: Global statistics (parametric or non-parametric)
Number of subjects: 111
Study 2218184 — intervention group
Group type: EXPERIMENTAL
Intervention: Univariate ANOVA
Number of subjects: 111
Study 2218184 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonferroni adjustment
Number of subjects: 111
Study 2218184 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-parametric methods
Number of subjects: 111
Study 6153953 — intervention group
Group type: EXPERIMENTAL
Intervention: +cyanidanol-3
Number of subjects: 73
Study 6153953 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 30739519 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 13
Study 30739519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 28297050 — intervention group
Group type: EXPERIMENTAL
Intervention: Computational model‐aided decision making
Number of subjects: 372
Study 28297050 — intervention group
Group type: COMPARATOR
Intervention: Conventional healthcare
Number of subjects: 372
Study 25407559 — intervention group
Group type: EXPERIMENTAL
Intervention: O(6)-benzylguanine (O(6)-BG) + BCNU 40 mg/m² + radiation therapy (RT)
Number of subjects: 183
Study 25407559 — intervention group
Group type: COMPARATOR
Intervention: BCNU 200 mg/m² + RT
Number of subjects: 183
Study 24267123 — intervention group
Group type: COMPARATOR
Intervention: Tamsulosin hydrochloride 0.4 mg
Number of subjects: 400
Study 24267123 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin hydrochloride 0.4 mg plus meloxicam 15 mg
Number of subjects: 400
Study 21193925 — intervention group
Group type: EXPERIMENTAL
Intervention: National/international level surfers (NIN)
Number of subjects: 17
Study 21193925 — intervention group
Group type: COMPARATOR
Intervention: Local level surfers (LOC)
Number of subjects: 17
Study 21193925 — intervention group
Group type: EXPERIMENTAL
Intervention: NIN surfers
Number of subjects: 17
Study 19711612 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan dentifrice (0.3%)
Number of subjects: 60
Study 19711612 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (Control)
Number of subjects: 60
Study 17503104 — intervention group
Group type: EXPERIMENTAL
Intervention: MDD-PTSD+ patients
Number of subjects: 677
Study 17503104 — intervention group
Group type: COMPARATOR
Intervention: MDD patients
Number of subjects: 677
Study 15542510 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori testing plus eradication therapy
Number of subjects: 500
Study 15542510 — intervention group
Group type: COMPARATOR
Intervention: Prompt endoscopy
Number of subjects: 500
Study 11583187 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel plus doxorubicin (A) combination therapy
Number of subjects: 657
Study 9779497 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% salt water bath
Number of subjects: 24
Study 9779497 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% salt water bath
Number of subjects: 24
Study 9779497 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% salt water bath
Number of subjects: 24
Study 9779497 — intervention group
Group type: EXPERIMENTAL
Intervention: tap water bath
Number of subjects: 24
Study 7878580 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drainage
Number of subjects: 307
Study 2405764 — intervention group
Group type: COMPARATOR
Intervention: No drain
Number of subjects: 307
Study 2405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture of the cavity
Number of subjects: 307
Study 2405764 — intervention group
Group type: COMPARATOR
Intervention: No suture
Number of subjects: 307
Study 2405764 — intervention group
Group type: EXPERIMENTAL
Intervention: Penrose drain
Number of subjects: 307
Study 373651 — intervention group
Group type: EXPERIMENTAL
Intervention: prednisolone t-butyl acetate
Number of subjects: 30
Study 373651 — intervention group
Group type: EXPERIMENTAL
Intervention: methyl prednisolone acetate
Number of subjects: 30
Study 373651 — intervention group
Group type: EXPERIMENTAL
Intervention: triamcinolone hexacetonide
Number of subjects: 30
Study 30866674 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian results
Number of subjects: 933
Study 30866674 — intervention group
Group type: COMPARATOR
Intervention: Frequentist results
Number of subjects: 933
Study 30646209 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-week qigong intervention (n=136)
Number of subjects: 271
Study 30646209 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (n=135)
Number of subjects: 271
Study 28449631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 µg/kg followed by 0.5 µg/kg/h until abdominal closure
Number of subjects: 40
Study 28449631 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 40
Study 28449631 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS)
Number of subjects: 40
Study 25863753 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) with 30 Gy to the site of residual disease
Number of subjects: 2126
Study 25863753 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequately performed RT
Number of subjects: 2126
Study 25863753 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate RT
Number of subjects: 2126
Study 22790909 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient treatment
Number of subjects: 530
Study 22790909 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 530
Study 21084567 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitoring
Number of subjects: 39
Study 20024718 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-selected treatment partners
Number of subjects: 375
Study 20024718 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based treatment partners
Number of subjects: 375
Study 20024718 — intervention group
Group type: COMPARATOR
Intervention: No treatment partner
Number of subjects: 375
Study 17067318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium (2-140 mg single dose, 8-70 mg twice daily)
Number of subjects: 80
Study 17067318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 17067318 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimosiamose disodium (doses > or =50 mg given twice daily and 105 mg once daily)
Number of subjects: 80
Study 15325680 — intervention group
Group type: EXPERIMENTAL
Intervention: High wheat bran fiber (WBF) supplementation (13.5 g/d)
Number of subjects: 237
Study 15325680 — intervention group
Group type: COMPARATOR
Intervention: Low wheat bran fiber (WBF) supplementation (2 g/d)
Number of subjects: 237
Study 11572281 — intervention group
Group type: EXPERIMENTAL
Intervention: Humidified conditions
Number of subjects: 463
Study 11572281 — intervention group
Group type: COMPARATOR
Intervention: Nonhumidified conditions
Number of subjects: 463
Study 9564804 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg Fel d 1 peptides
Number of subjects: 22
Study 9564804 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 microg Fel d 1 peptides
Number of subjects: 22
Study 9564804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 9564804 — intervention group
Group type: COMPARATOR
Intervention: Control (tetanus toxoid)
Number of subjects: 22
Study 7940720 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 HLA-DR antigen-matched blood
Number of subjects: 2
Study 7940720 — intervention group
Group type: COMPARATOR
Intervention: Random blood
Number of subjects: 2
Study 3108909 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 24
Study 3108909 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 24
Study 3108909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31367901 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone-releasing hydrogel
Number of subjects: 60
Study 31367901 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amiodarone-releasing hydrogel)
Number of subjects: 60
Study 29171979 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushion group (dynamic cushion)
Number of subjects: 30
Study 29171979 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 26942345 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational group B streptococcal vaccine
Number of subjects: 86
Study 26942345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 25716880 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive rehabilitation with MS-Line!
Number of subjects: 43
Study 25716880 — intervention group
Group type: COMPARATOR
Intervention: No cognitive rehabilitation (Control)
Number of subjects: 43
Study 23771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash with chromic catgut sutures
Number of subjects: 100
Study 23771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline mouth wash with chromic catgut sutures
Number of subjects: 100
Study 23771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouth wash with vicryl sutures
Number of subjects: 100
Study 23771456 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm saline mouth wash with vicryl sutures
Number of subjects: 100
Study 23771456 — intervention group
Group type: COMPARATOR
Intervention: Warm water mouth wash with vicryl sutures
Number of subjects: 100
Study 19967581 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-leg heel raises
Number of subjects: 20
Study 19967581 — intervention group
Group type: EXPERIMENTAL
Intervention: Rowing ergometer exercise
Number of subjects: 20
Study 19130855 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga based lifestyle intervention
Number of subjects: 77
Study 19130855 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 77
Study 16645152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET (175 microg/275 microg)
Number of subjects: 90
Study 16645152 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA (1 mg/0.5 mg)
Number of subjects: 90
Study 16645152 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal E2/NET
Number of subjects: 90
Study 16645152 — intervention group
Group type: COMPARATOR
Intervention: Oral E2/NETA
Number of subjects: 90
Study 14652672 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy (50.4 Gy for pN0 or 54.0 Gy for pN1/x)
Number of subjects: 36
Study 14652672 — intervention group
Group type: EXPERIMENTAL
Intervention: External-beam radiotherapy
Number of subjects: 36
Study 10988126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (84 microgram)
Number of subjects: 0
Study 10988126 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 0
Study 10988126 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear surgical margins (n = 134)
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Close surgical margins (n = 6)
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved surgical margins (n = 11)
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Close or involved margins (n = 14)
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Margins > 5 mm
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Margins < 5 mm
Number of subjects: 159
Study 8774917 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative complications (fistula rates)
Number of subjects: 159
Study 1296490 — intervention group
Group type: EXPERIMENTAL
Intervention: ioversol 300
Number of subjects: 79
Study 1296490 — intervention group
Group type: COMPARATOR
Intervention: iopromide 300
Number of subjects: 79
Study 6385878 — intervention group
Group type: EXPERIMENTAL
Intervention: cefoxitin 2 grams every 6 hours
Number of subjects: 152
Study 6385878 — intervention group
Group type: EXPERIMENTAL
Intervention: cefamandole 2 grams every 4 hours
Number of subjects: 152
Study 6385878 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarcillin 3 grams every 4 hours and tobramycin 1.5 mg/kg every 8 hours
Number of subjects: 152
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: Predominant hypoautofluorescence precursor lesions
Number of subjects: 109
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal change autofluorescence precursor lesions
Number of subjects: 109
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: Geographic atrophy evolving from minimal change autofluorescence precursor lesions
Number of subjects: 109
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: Incident GA
Number of subjects: 109
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: GA arising from predominantly normal autofluorescence
Number of subjects: 109
Study 31153849 — intervention group
Group type: EXPERIMENTAL
Intervention: Faster GA enlargement rates
Number of subjects: 109
Study 30116124 — intervention group
Group type: EXPERIMENTAL
Intervention: HIIT
Number of subjects: 12
Study 30116124 — intervention group
Group type: COMPARATOR
Intervention: CET
Number of subjects: 12
Study 25955866 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX infusion at 0.5 μg/kg/h for 10 min and then adjusted to 0.2 to 0.5 μg/kg/h
Number of subjects: 60
Study 25955866 — intervention group
Group type: EXPERIMENTAL
Intervention: DEX infusion
Number of subjects: 60
Study 25955866 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 60
Study 24845086 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced tipping-point displays
Number of subjects: 0
Study 24845086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensitivity analyses
Number of subjects: 0
Study 24845086 — intervention group
Group type: EXPERIMENTAL
Intervention: Tipping-point analysis
Number of subjects: 0
Study 22202972 — intervention group
Group type: EXPERIMENTAL
Intervention: Daikenchuto (DKT) 7.5 g/day from the day after surgery until the 7th postoperative day
Number of subjects: 30
Study 22202972 — intervention group
Group type: COMPARATOR
Intervention: Control group (no DKT)
Number of subjects: 30
Study 19451347 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel
Number of subjects: 13608
Study 19451347 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13608
Study 18200396 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 0
Study 18200396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16296572 — intervention group
Group type: EXPERIMENTAL
Intervention: nebivolol 5 mg once daily
Number of subjects: 314
Study 16296572 — intervention group
Group type: COMPARATOR
Intervention: losartan 50 mg once daily
Number of subjects: 314
Study 16296572 — intervention group
Group type: EXPERIMENTAL
Intervention: both treatments
Number of subjects: 314
Study 12063454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1 g before skin incision, 400 mg/h during operation, and 500 mg in pump priming)
Number of subjects: 60
Study 12063454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 60
Study 12063454 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 60
Study 9706922 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane (0.25%‐1%)
Number of subjects: 90
Study 9706922 — intervention group
Group type: COMPARATOR
Intervention: Propofol (50‐200 microg x kg(‐1) x min(‐1))
Number of subjects: 90
Study 9706922 — intervention group
Group type: COMPARATOR
Intervention: Desflurane (1.4%‐6%)
Number of subjects: 90
Study 9706922 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane, Propofol, Desflurane
Number of subjects: 90
Study 9706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 90
Study 9706922 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 90
Study 8582464 — intervention group
Group type: EXPERIMENTAL
Intervention: Hamamelis distillate cream (5.35 g hamamelis distillate with 0.64 mg ketone/100 g)
Number of subjects: 72
Study 8582464 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% hydrocortisone cream
Number of subjects: 72
Study 8582464 — intervention group
Group type: COMPARATOR
Intervention: Drug-free vehicle
Number of subjects: 72
Study 2223342 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric 0.19% bupivacaine
Number of subjects: 29
Study 2223342 — intervention group
Group type: COMPARATOR
Intervention: Plain 0.5% bupivacaine
Number of subjects: 29
Study 27205 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimiterol (500 microgram)
Number of subjects: 10
Study 27205 — intervention group
Group type: COMPARATOR
Intervention: Orciprenaline (1.5 mg)
Number of subjects: 10
Study 31995130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication alone
Number of subjects: 0
Study 31995130 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication in combination with cognitive behavioral therapy
Number of subjects: 0
Study 31995130 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 30935866 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifemin (cimicifuga racemose extract) combined with LHRH-a
Number of subjects: 85
Study 30935866 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard treatment of LHRH-a)
Number of subjects: 85
Study 29028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptation of the PK model applied at 60 min
Number of subjects: 120
Study 29028925 — intervention group
Group type: COMPARATOR
Intervention: Population-based PK model (control)
Number of subjects: 120
Study 29028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Bayesian adaptation of the PK model
Number of subjects: 120
Study 29028925 — intervention group
Group type: EXPERIMENTAL
Intervention: Eleveld propofol PK model
Number of subjects: 120
Study 26041437 — intervention group
Group type: EXPERIMENTAL
Intervention: ScvO2 group
Number of subjects: 79
Study 26041437 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 23524116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention groups (pre‐ or postnatal education)
Number of subjects: 119
Study 23524116 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal education group
Number of subjects: 119
Study 23524116 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 119
Study 22226275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion at 2 pmol/kg/min for 72 hours
Number of subjects: 10
Study 22226275 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 10
Study 22226275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic polypeptide (PP) infusion
Number of subjects: 10
Study 19687024 — intervention group
Group type: EXPERIMENTAL
Intervention: Glatiramer acetate (GA)
Number of subjects: 75
Study 19687024 — intervention group
Group type: COMPARATOR
Intervention: Interferon beta-1b (IFNbeta1b)
Number of subjects: 75
Study 19687024 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (GA and IFNbeta1b)
Number of subjects: 75
Study 17596064 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon‐alpha
Number of subjects: 0
Study 17596064 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin‐2
Number of subjects: 0
Study 17596064 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow transplantation
Number of subjects: 0
Study 17596064 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel therapeutic approaches based on inhibition of angiogenesis
Number of subjects: 0
Study 15579335 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (Rispoval 4)
Number of subjects: 83
Study 11499722 — intervention group
Group type: EXPERIMENTAL
Intervention: PVS-guided antiarrhythmic drug therapy (n = 142)
Number of subjects: 704
Study 11499722 — intervention group
Group type: COMPARATOR
Intervention: No antiarrhythmic therapy (controls, n = 353)
Number of subjects: 704
Study 11499722 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (specific agent)
Number of subjects: 704
Study 9592629 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 94
Study 9592629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 7995387 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via p‐MDI (0.25 mg)
Number of subjects: 10
Study 7995387 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline via Turbuhaler (0.25 mg)
Number of subjects: 10
Study 7995387 — intervention group
Group type: COMPARATOR
Intervention: Placebo p‐MDI (no terbutaline)
Number of subjects: 10
Study 2892739 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin suppositories (2 X 100 mg)
Number of subjects: 60
Study 2892739 — intervention group
Group type: COMPARATOR
Intervention: Placebo suppositories
Number of subjects: 60
Study 30974501 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion threshold (Hb < 75 g L‐1)
Number of subjects: 0
Study 30974501 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion threshold (Hb < 95 g L‐1 in intensive care and < 85 g L‐1 outside intensive care)
Number of subjects: 0
Study 27705888 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 7297
Study 27705888 — intervention group
Group type: COMPARATOR
Intervention: nsNSAIDs
Number of subjects: 7297
Study 26686785 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid Arthritis‐Work Instability Scale (RA‐WIS)
Number of subjects: 148
Study 23925396 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sildenafil citrate (100 mg single dose)
Number of subjects: 62